Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Eniluracil has potential to make the chemotherapy staple 5-fluorouracil more effective, safer and orally active, Adherex maintains. Agent slated to enter new Phase III studies in 2007. Licensing pact valued at up to $220 mil. also gives GSK option on Adherex’ angiolytic agent Exherin.